<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714385</url>
  </required_header>
  <id_info>
    <org_study_id>Medtronic PSR TDD PMCF</org_study_id>
    <nct_id>NCT04714385</nct_id>
  </id_info>
  <brief_title>Medtronic PSR TDD PMCF</brief_title>
  <official_title>Product Surveillance Registry (PSR) - Targeted Drug Delivery (TDD) - SynchroMed II European Post-Market Clinical Follow-up (PMCF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide continuing evaluation and reporting of safety and&#xD;
      performance of the SynchroMed II Infusion System within its intended use. Data will support&#xD;
      post-market surveillance obligations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was originally posted under NCT01524276 and now posted alone to adapt to new ISO&#xD;
      regulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 9, 2017</start_date>
  <completion_date type="Anticipated">August 27, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 27, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pump accuracy</measure>
    <time_frame>4 years</time_frame>
    <description>Demonstrate that the proportion of subjects treated as intended (p) with flow rate accuracy outside the interval of 0.75 to 1.25 (Â±25 percent) is &lt; 10 percent with 95 percent confidence at 4 years post implant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pump survival</measure>
    <time_frame>4 years</time_frame>
    <description>Demonstrate pump survival (freedom from product performance events) is &gt; 90 percent at 4 years post-pump implant</description>
  </secondary_outcome>
  <enrollment type="Actual">209</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Spasticity, Muscle</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients implanted with SynchroMed II Model 8637 Programmable Pump who meet approved&#xD;
        indications (Chronic pain and severe spasticity)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient or legally authorized representative provides written authorization and/or&#xD;
             consent per institution and geographical requirements&#xD;
&#xD;
          -  Patient has or is intended to receive or be treated with an eligible Medtronic product&#xD;
&#xD;
          -  Patient within enrollment window relative to therapy initiation or meets criteria for&#xD;
             retrospective enrollment&#xD;
&#xD;
          -  The indication for implant meets approved indications&#xD;
&#xD;
          -  The patient can reasonably be expected to remain fully on label for a 48-month time&#xD;
             period after implant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who is, or will be, inaccessible for follow-up&#xD;
&#xD;
          -  Patient with exclusion criteria required by local law&#xD;
&#xD;
          -  Patient is currently enrolled in or plans to enroll in any concurrent drug and/or&#xD;
             device study that may confound results&#xD;
&#xD;
          -  There is no indication at enrollment (e.g., medical conditions, anticipated&#xD;
             relocation, etc.) that the patient will be unable to complete 48 months of follow-up&#xD;
             after implant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brugge</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roeselare</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint-Niklaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilrijk</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praha</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Enschede</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Badalona</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morges</name>
      <address>
        <city>Morges</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottwil</name>
      <address>
        <city>Nottwil</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlesbrough</name>
      <address>
        <city>Middlesbrough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

